DNA based covid-19 shot approved by India


India has given its first DNA-based Covid-19 vaccine emergency use approval as the world’s second-worst-hit nation looks to boost its vaccination drive in the face of a possible third wave of corona infection.
On Friday (Aug 20), the government said that a three-dose vaccine developed by Ahmedabad-based Cadila Healthcare had been approved. In clinical studies in July, the vaccine exhibited a 67 percent efficacy against symptomatic Covid-19. This is the second shot created locally that has been approved.
According to Cadila, the vaccine, which acts against newer coronavirus strains, including the highly infectious Delta version, contributes to the country’s armory in the fight against the virus.
Covid-19 has affected about 32.3 million people in South Asia and killed over 433,049 people, particularly during a catastrophic second wave a few months ago.
Faster vaccinations, which have been shown to minimize hospitalization and fatalities, are critical to preventing future viral outbreaks in densely populated countries.
Cadila claimed in a statement that the vaccine is “the world’s first and India’s indigenously created DNA-based vaccine for Covid-19 to be administered in humans, including children and adults 12 years and above.”
India has now approved six vaccines, despite only 9% of its population having been adequately immunized. AstraZeneca’s two and Hyderabad-based Bharat Biotech International’s one are already widely used.
Sputnik V vaccination from Russia has been given out in tiny numbers. In contrast, Johnson & Johnson and Moderna doses have not been utilized since the manufacturers are still negotiating for legal indemnity.


Please enter your comment!
Please enter your name here

Enable Google Transliteration.(To type in English, press Ctrl+g)